Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Posted on by

Continues to Expand Viatris’ Innovative Portfolio in Cardiovascular Diseases Leverages Viatris’ Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotagliflozin to Additional Indications PITTSBURGH, Oct. 16, 2024 /PRNewswire/ — Viatris Inc….

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.